Celltrion received approval of Phase 3 clinical trial pla of 'CT-P10'

Published: 2014-07-01 15:57:29

Updated: 2014-07-01 15:57:29

On June 29, Ministry of Food and Drug Safety approved Phase 3 clinical trial pla of 'CT-P10' from Celltrion. 'CT-P10' is a biosimilar product of MabThera (ingredient name: rituximab) which is for the treatment of rheumatoid arthritis and non-Hodgkin's lymphoma.

The Phase 3 clinical trial will be proceeded in hospitals including Guro Hospital, Dankook University Hospital, Samsung Medical Center...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.